The future potential for cocaine vaccines

Bibliography

• Degenhardt L, Baxter AJ, Lee YY, et al. The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010. Drug Alcohol Depend 2014;137:36-47
   PubMed Web of Science ®Google Scholar
• Robles G, Calderon G, Magaloni B. The economic consequences of drug trafficking violence in Mexico. 2013. Available from: http://iisdb.stanford.edu/pubs/24014/RoblesCalderonMagaloni_EconCosts5.pdf [Cited 31 January 2014]
   Google Scholar
• Wyler LS. International drug control policy: background and U.S. responses. August 13, 2013 crime economics implications for US and other countries]. 2013. Available from: http://www.fas.org/sgp/crs/row/RL34543.pdf [Cited 31 January 2014]
   Google Scholar
• Results from the 2012 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration, Rockville, MD. 2013. Available from: http://oas.samhsa.gov
   Google Scholar
• UNODC, World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6). 2013. Available from: http://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf [Cited 31 January 2014]
   Google Scholar
• O’Brien MS, Anthony JC. Risk of becoming cocaine dependent: epidemiological estimates for the United States 2000-2001. Neuropsychopharmacology 2005;30(5):1006-18
   PubMed Web of Science ®Google Scholar
• Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002;26(4):479-88
   PubMed Web of Science ®Google Scholar
• Shorter D, Kosten TR. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med 2011;9:119
   PubMed Web of Science ®Google Scholar
• Orson FM, Kinsey BM, Singh RA, et al. Vaccines for cocaine abuse. Hum Vaccin 2009;5(4):194-9
   PubMed Web of Science ®Google Scholar
• Paula S, Tabet MR, Farr CD, et al. Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody. J Med Chem 2004;47(1):133-42
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009;66(10):1116-23
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011;89(3):392-9
   PubMed Web of Science ®Google Scholar
• Rolla S, Ria F, Occhipinti S, et al. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 2010;184(11):6124-32
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Pulendran B. Immunogenomics and systems biology of vaccines. Immunol Rev 2011;239(1):197-208
   PubMed Web of Science ®Google Scholar
• Martinetti M, De Silvestri A, Belloni C, et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 2000;97(3):234-40
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Poland GA. Vaccinomics: current findings, challenges and novel approaches for vaccine development. Apps J 2011;13(3):438-44
   PubMed Web of Science ®Google Scholar
• Bonds MH, Rohani P. Herd immunity acquired indirectly from interactions between the ecology of infectious diseases, demography and economics. J R Soc Interface 2010;7(44):541-7
   PubMed Web of Science ®Google Scholar
• Dhiman N, Ovsyannikova IG, Vierkant RA, et al. Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. Tissue Antigens 2008;72(3):211-20
   PubMed Web of Science ®Google Scholar
• Chen J, Liang Z, Lu F, et al. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 2011;29(4):706-11
   PubMed Web of Science ®Google Scholar
• Dhiman N, Ovsyannikova IG, Vierkant RA, et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008;26(14):1731-6
   PubMed Web of Science ®Google Scholar
• Wiertsema SP, Baynam G, Khoo SK, et al. Impact of genetic variants in IL-4, IL-4 RA and IL-13 on the anti-pneumococcal antibody response. Vaccine 2007;25(2):306-13
   PubMed Web of Science ®Google Scholar
• Saveliev A, Tybulewicz VL. Lymphocyte signaling: beyond knockouts. Nat Immunol 2009;10(4):361-4
   PubMed Web of Science ®Google Scholar
• Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420(6915):520-62
   PubMed Web of Science ®Google Scholar
• Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58(2):158-64
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol 2002;26(7):382-92
   PubMed Web of Science ®Google Scholar
• Ramakrishnan M, Alves De Melo F, Kinsey BM, et al. Probing cocaine-antibody interactions in buffer and human serum. PLoS One 2012;7(7):e40518
   PubMed Web of Science ®Google Scholar
• Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry 2011;2:64
   Google Scholar
• Samaha AN, Li Y, Robinson TE. The rate of intravenous cocaine administration determines susceptibility to sensitization. J Neurosci 2002;22(8):3244-50
   PubMed Web of Science ®Google Scholar
• Samaha AN, Mallet N, Ferguson SM, et al. The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J Neurosci 2004;24(28):6362-70
   PubMed Web of Science ®Google Scholar
• Smith BJ, Jones HE, Griffiths RR. Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology (Berl) 2001;156(4):435-44
   PubMed Web of Science ®Google Scholar
• Woolverton WL, Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 2004;486(3):251-7
   PubMed Web of Science ®Google Scholar
• Abreu ME, Bigelow GE, Fleisher L, Walsh SL. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 2001;154(1):76-84
   PubMed Web of Science ®Google Scholar
• Nelson RA, Boyd SJ, Ziegelstein RC, et al. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 2006;82(1):19-24
   PubMed Web of Science ®Google Scholar
• Orson FM, Kinsey BM, Ramakrishnan M, et al. Immunotherapeutic vaccines for substance abuse. In: Canales JJ, editor. Emerging targets for drug addiction treatment. NOVA Publishers, New York, USA; 2012
   Google Scholar
• Newton TF, De La Garza R II, Kalechstein AD, Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol Biochem Behav 2005;82(1):90-7
   PubMed Web of Science ®Google Scholar
• Jufer RA, Wstadik A, Walsh SL, et al. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol 2000;24(7):467-77
   PubMed Web of Science ®Google Scholar
• Cai X, Whitfield T, Hixon MS, et al. Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design. J Med Chem 2013;56(9):3701-9
   PubMed Web of Science ®Google Scholar
• Cai X, Whitfield T, Moreno AY, et al. Probing the effects of hapten stability on cocaine vaccine immunogenicity. Mol Pharm 2013;10(11):4176-84
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010;67(1(59):65
   Web of Science ®Google Scholar
• Orson FM, Kinsey BM, Singh RA, et al. The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep 2007;9(5):381-7
   PubMedGoogle Scholar
• Orson FM, Rossen RD, Shen X, et al. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict 2013;22(2):169-74
   PubMed Web of Science ®Google Scholar
• Stevens RH, Saxon A. Reduced in vitro production of anti-tetanus toxoid antibody after repeated in vivo immunization with tetanus toxoid. J Immunol 1979;122(2):592-8
   PubMed Web of Science ®Google Scholar
• Deng SX, Bharat N, Fischman MC, Landry DW. Covalent modification of proteins by cocaine. Proc Natl Acad Sci USA 2002;99(6):3412-16
   PubMed Web of Science ®Google Scholar
• Pellegrino TC, Dunn KL, Bayer BM. Mechanisms of cocaine-induced decreases in immune cell function. Int Immunopharmacol 2001;1(4):665-75
   PubMed Web of Science ®Google Scholar
• Ananthan D, Shah S, Koya HH, et al. Levamisole tainted cocaine: an emerging health issue. QJM 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Tallarida CS, Egan E, Alejo GD, et al. Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine’s action in vivo. Neuropharmacology 2014;79:590-5
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Savan R, Qi Y, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011;472(7344):495-8
   PubMed Web of Science ®Google Scholar
• Hohler T, Stradmann-Bellinghausen B, Starke R, et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002;37(3):387-92
   PubMed Web of Science ®Google Scholar
• De Silvestri A, Pasi A, Martinetti M, et al. Family study of non-responsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes Immun 2001;2(7):367-72
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Schaid DJ, Vierkant RA, et al. Associations between measles antibody levels and the protein structure of class II human leukocyte antigens. Hum Immunol 2003;64(7):696-707
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Haralambieva IH, Vierkant RA, et al. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 2011;130(4):547-61
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 2013;12(3):323-32
   PubMed Web of Science ®Google Scholar
• Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and methamphetamine. Br J Clin Pharmacol 2014;77(2):368-74
   PubMed Web of Science ®Google Scholar
• Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav 2009;92(2):199-205
   PubMed Web of Science ®Google Scholar
• Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010;10(4):225-35
   PubMed Web of Science ®Google Scholar
• Ariffin JK, Sweet MJ. Differences in the repertoire, regulation and function of Toll-like receptors and inflammasome-forming nod-like receptors between human and mouse. Curr Opin Microbiol 2013;16(3):303-10
   PubMed Web of Science ®Google Scholar
• Moesta AK, Graef T, Abi-Rached L, et al. Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. J Immunol 2008;185(7):4233-7
   Web of Science ®Google Scholar
• Shultz LD, Brehm MA, Bavari S, Greiner DL. Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann NY Acad Sci 2011;1245:50-4
   PubMed Web of Science ®Google Scholar
• Yu CI, Gallegos M, Marches F, et al. Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood 2008;112(9):3671-8
   PubMed Web of Science ®Google Scholar
• Brehm MA, Cuthbert A, Yang C, et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 2010;135(1):84-98
   PubMed Web of Science ®Google Scholar
• Lang J, Weiss N, Freed BM, et al. Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2null Il2rgammanull mouse model: a multivariable optimization approach. Clin Immunol 2011;140(1):102-16
   PubMed Web of Science ®Google Scholar
• Akkina R. Human immune responses and potential for vaccine assessment in humanized mice. Curr Opin Immunol 2013;25(3):403-9
   PubMed Web of Science ®Google Scholar
• Spranger S, Frankenberger B, Schendel DJ. NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med 2012;10:30
   PubMed Web of Science ®Google Scholar
• Ramer PC, Chijioke O, Meixlsperger S, et al. Mice with human immune system components as in vivo models for infections with human pathogens. Immunol Cell Biol 2011;89(3):408-16
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Yokota T, Kastelein R, et al. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol 1987;138(6):1813-16
   PubMed Web of Science ®Google Scholar
• Zou JJ, Schoenhaut DS, Carvajal DM, et al. Structure-function analysis of the p35 subunit of mouse interleukin 12. J Biol Chem 1995;270(11):5864-71
   PubMed Web of Science ®Google Scholar
• Shpall EJ, Jones RB, Bearman SI, et al. Peripheral blood stem cell transplantation in breast cancer. Baillieres Best Pract Res Clin Haematol 1999;12(1-2):219-32
   PubMed Web of Science ®Google Scholar
• Larocque A, Hoffman RS. Levamisole in cocaine: unexpected news from an old acquaintance. Clin Toxicol (Phila) 2004;50(4):231-41
   Web of Science ®Google Scholar
• Graf J, Lynch K, Yeh CL, et al. Purpura, cutaneous necrosis, and antineutrophil cytoplasmic antibodies associated with levamisole-adulterated cocaine. Arthritis Rheum 2011;63(12):3998-4001
   PubMed Web of Science ®Google Scholar
• Buonaguro FM, Tornesello ML, Buonaguro L. New adjuvants in evolving vaccine strategies. Expert Opin Biol Ther 2011;11(7):827-32
   PubMed Web of Science ®Google Scholar
• Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008;105(30):10501-6
   PubMed Web of Science ®Google Scholar
• Wilson-Welder JH, Torres MP, Kipper MJ, et al. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009;98(4):1278-316
   PubMed Web of Science ®Google Scholar
• Lai Z, Schreiber JR. Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM(1)(9)(7) conjugate vaccine. Clin Vaccine Immunol 2011;18(5):724-9
   PubMed Web of Science ®Google Scholar
• Carlin G, Viitanen E. In vitro pyrogenicity of the diphtheria, tetanus and acellular pertussis components of a trivalent vaccine. Vaccine 2005;23(28):3709-15
   PubMed Web of Science ®Google Scholar
• Hicks MJ, De BP, Rosenberg JB, et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 2011;19(3):612-19
   PubMed Web of Science ®Google Scholar
• Wee S, Hicks MJ, De BP, et al. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 2011;37(5):1083-91
   PubMed Web of Science ®Google Scholar
• Hicks MJ, Kaminsky SM, De BP, et al. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anti-cocaine vaccine. Hum Gene Ther Clin Dev 2014; Epub ahead of print
   Google Scholar
• Orson FM, Kinsey BM, Singh RA, et al. Substance abuse vaccines. Ann N Y Acad Sci 2008;1141:257-69
   PubMedGoogle Scholar
• Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014;14(3):154-65
   PubMed Web of Science ®Google Scholar
• Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005;4(6):351-63
   PubMed Web of Science ®Google Scholar
• Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8(2):191-7
   PubMed Web of Science ®Google Scholar
• Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27(1):18-20
   PubMed Web of Science ®Google Scholar
• Elia L, Aurisicchio L, Facciabene A, et al. CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther 2007;14(2):201-10
   PubMed Web of Science ®Google Scholar
• Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009;1174:99-106
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5(10):987-95
   PubMed Web of Science ®Google Scholar
• Cui J, Li Y, Zhu L, et al. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat Immunol 2012;13(4):387-95
   PubMed Web of Science ®Google Scholar
• Cui J, Zhu L, Xia X, et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010;141(3):483-96
   PubMed Web of Science ®Google Scholar
• Xia X, Cui J, Wang HY, et al. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 2011;34(6):843-53
   PubMed Web of Science ®Google Scholar
• Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005;309(5739):1380-4
   PubMed Web of Science ®Google Scholar
• Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13(23):6947-58
   PubMed Web of Science ®Google Scholar
• Peng G, Wang HY, Peng W, et al. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007;27(2):334-48
   PubMed Web of Science ®Google Scholar
• Chung Y, Tanaka S, Chu F, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 2011;17(8):983-8
   PubMed Web of Science ®Google Scholar
• Kim HJ, Verbinnen B, Tang X, et al. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 2010;467(7313):328-32
   PubMed Web of Science ®Google Scholar
• Linterman MA, Pierson W, Lee SK, et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med 2011;17(8):975-82
   PubMed Web of Science ®Google Scholar
• Secades-Villa R, Garcia-Fernandez G, Pena-Suarez E, et al. Contingency management is effective across cocaine-dependent outpatients with different socioeconomic status. J Subst Abuse Treat 2013;44(3):349-54
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Gao Y. Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem 2012;4(2):151-62
   PubMed Web of Science ®Google Scholar
• Gao Y, LaFleur D, Shah R, et al. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact 2008;175(1-3):83-7
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Gao Y, Anker JJ, et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 2008;33(11):2715-25
   PubMed Web of Science ®Google Scholar
• Teva PI. Efficacy and safety of TV-1380 as treatment for facilitation of abstinence in cocaine-dependent subjects. 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01887366
   Google Scholar
• Byrne BJ. Pathway for approval of a gene therapy orphan product: treading new ground. Mol Ther 2013;21(8):1465-6
   PubMed Web of Science ®Google Scholar
• Geng L, Gao Y, Chen X, et al. Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One 2013;8(6):e67446
   PubMed Web of Science ®Google Scholar
• Zlebnik NE, Brimijoin S, Gao Y, et al. Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology 2014;39(6):1538-46
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene 2013;525(2):174-81
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58
   PubMed Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15(12):1157-66
   PubMed Web of Science ®Google Scholar
• Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 2009;106(38):16363-8
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Ng P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet 2011;20(R1):R7-13
   PubMed Web of Science ®Google Scholar
• Morral N, O’Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999;96(22):12816-21
   PubMed Web of Science ®Google Scholar
• Vetrini F, Ng P. Liver-directed gene therapy with helper-dependent adenoviral vectors: current state of the art and future challenges. Curr Pharm Des 2011;17(24):2488-99
   PubMed Web of Science ®Google Scholar
• Seregin SS, Appledorn DM, McBride AJ, et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009;17(4):685-96
   PubMed Web of Science ®Google Scholar
• Lufino MM, Edser PA, Wade-Martins R. Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol Ther 2008;16(9):1525-38
   PubMed Web of Science ®Google Scholar
• Brimijoin S, Orson F, Kosten TR, et al. Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. Chem Biol Interact 2012;203(1):212-16
   PubMed Web of Science ®Google Scholar
• Gao Y, Geng L, Orson F, et al. Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. Chem Biol Interact 2012;203(1):208-11
   PubMed Web of Science ®Google Scholar
• Carroll ME, Zlebnik NE, Anker JJ, et al. Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS One 2012;7(8):e43536
   PubMed Web of Science ®Google Scholar
• Gao Y, Orson FM, Kinsey B, et al. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact 2010;187(1-3):421-4
   PubMed Web of Science ®Google Scholar
• Rosenberg JB, Hicks MJ, De BP, et al. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther 2012;23(5):451-9
   PubMed Web of Science ®Google Scholar
• Garcia-Fernandez G, Secades-Villa R, Garcia-Rodriguez O, et al. Long-term benefits of adding incentives to the community reinforcement approach for cocaine dependence. Eur Addict Res 2011;17(3):139-45
   PubMed Web of Science ®Google Scholar
• Stein MD, Herman DS, Anderson BJ. A motivational intervention trial to reduce cocaine use. J Subst Abuse Treat 2009;36(1):118-25
   PubMed Web of Science ®Google Scholar
• Anker JJ, Brimijoin S, Gao Y, et al. Cocaine hydrolase encoded in viral vector blocks the reinstatement of cocaine seeking in rats for 6 months. Biol Psychiatry 2012;71(8):700-5
   PubMed Web of Science ®Google Scholar